Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    NIAID | herpes genitalis
Show Display Options
RSS Create an RSS feed from your search for:
NIAID | herpes genitalis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
Conditions: HIV Infections;   Herpes Genitalis
Interventions: Drug: Acyclovir;   Drug: Placebo
2 Recruiting Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Conditions: Genital Herpes;   Herpes Simplex Virus;   Herpes Simplex Virus Vaccines;   HSV Vaccines;   Herpesvirus Vaccines
Intervention: Biological: HSV529
3 Completed HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru
Conditions: HIV Infections;   Herpes Genitalis;   HIV Seronegativity;   Syphilis
Intervention:
4 Completed A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Conditions: HIV Infections;   HIV Seronegativity;   Herpes Genitalis
Interventions: Drug: Acyclovir;   Drug: Acyclovir placebo
5 Completed
Has Results
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Condition: Genital Herpes
Interventions: Drug: acyclovir;   Drug: matching placebo
6 Completed Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women
Condition: Ulcers of Female Genital Organs
Interventions: Drug: Acyclovir;   Drug: Placebo
7 Active, not recruiting Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Condition: Genital Herpes
Intervention: Drug: acyclovir
8 Completed
Has Results
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Conditions: HIV Infections;   HSV-2 Genital Herpes
Intervention: Drug: 3% SPL7013 Gel (VivaGel)

Indicates status has not been verified in more than two years